Spatially Fractionated Radiotherapy for Tumor Treatment
ConditionRadiotherapy-Induced Immune Priming
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorXu Zhi-yuan
About this trial
To explore the efficacy and toxicity of spatially fractionated radiotherapy in the treatment of tumors.
Eligibility criteria
Qualifiers
Patients with a bulky solid tumor with a maximum diameter >4 cm or a refractory solid tumor.
Disqualifiers
Tumors involving hollow viscera that are considered to have a clinically significant risk of bleeding or perforation.
Patients with impaired consciousness or who are unable to care for themselves.
Trial design
Treatments tested in this trial
- spatially fractionated radiotherapy
Treatment groups
126 Participants
are divided into 1 treatment groupSponsors and collaborators
Xu Zhi-yuan
Lead sponsor
The University of Hong Kong-Shenzhen Hospital
Sponsor institution
Source ClinicalTrials.gov